Thursday 28 Mar 2024
By
main news image

KUALA LUMPUR (May 24): My EG Services Bhd (MyEG) has inked a memorandum of understanding (MoU) to bring in a Covid-19 rapid breath test system to Malaysia.

In a bourse filing, the group announced that it had signed an MoU with Singapore-based Breathonix Pte Ltd, which has developed a real-time breath test system for Covid-19. The MoU expires on July 1.

The test is a non-invasive, accurate and affordable solution that can generate results within a minute, making it particularly suitable for mass screening in high-traffic locations, MyEG added.

Additionally, these can be administered by any trained personnel who do not need to be specifically medically trained professionals.

Users of the test are only required to simply exhale normally into a disposable one-way valve mouthpiece connected to a breath sampler.

“The game-changing breathalyzer test has underdone clinical trials at three locations, in particular Singapore and Dubai, conducted from June 2020 to April 2021 and has received provisional authorisation from Singapore’s Health Sciences Authority.

"Breathonix is also working with Singapore’s Ministry of Health for a deployment trial at Tuas Checkpoint, where incoming travellers will be screened alongside the current compulsory antigen rapid test,” said MyEG.

Following the MoU’s signing, MyEG will apply for the requisite regulatory approvals and certifications for the breath test to be made commercially available in Malaysia.

Upon completing the relevant approval process, MyEG will be appointed as Breathonix’s exclusive distribution partner to undertake the commercial sale and marketing of its technology and associated systems in Malaysia.

"The impending launch of the breath test is the latest addition to a growing range of Covid-19 related innovations that MyEG has introduced since the outbreak of the pandemic, which includes deep-throat saliva test kits, the MySafeTravel screening and quarantine arrangement system for travellers and the MySafeQ quarantine hotel accommodation programme for low-risk domestic Covid-19 patients, among others,” it added.

According to Bloomberg, Singapore has approved the breath test, noting that Breathonix is a National University of Singapore (NUS) spin-off startup.

At noon market close, shares in MyEG were 2.19% or four sen higher at RM1.87, valuing it at RM6.87 billion.

Edited ByKang Siew Li
      Print
      Text Size
      Share